Introduction
Mitogen-activated protein kinases (MAPKs) are evolutionarily conserved kinases that control many cellular processes. Eukaryotic cells contain several MAPK pathways that function in parallel and are activated by different extracellular stimuli. The p38 MAPK family includes four members: p38a, p38b, p38d and p38c, which are approximately 60% identical in their amino acid sequences, are encoded by different genes, and have different tissue expression patterns. Most cell types express substantial levels of p38a, whereas the other p38 MAPKs have more tissue-specific expression patterns. p38a was originally identified as a protein kinase implicated in stress and inflammatory responses [1] [2] [3] [4] . Activation of p38a is usually triggered by the MAPK kinases MKK3 and MKK6, although sometimes by MKK4 or by autophosphorylation independently of MAPK kinases. More than 100 proteins can be directly phosphorylated by p38a, including other protein kinases and many transcription factors [5, 6] . The number and variety of p38a substrates identified is consistent with the ability of this signaling pathway to regulate numerous cellular processes. Indeed, the use of pyridinyl imidazole inhibitors such as SB203580 and SB202190, which inhibit p38a and p38b, has allowed the identification of many functions potentially regulated by p38 MAPKs beyond the stress response [7, 8] .
In vivo physiological roles for p38 MAPK signaling have been determined by the generation of genetically modified mice. Of note, p38a knockout (KO) mice are embryonic lethal as a result of a defect in placenta morphogenesis [9, 10] , whereas the KOs for other p38 MAPKs are viable [11, 12] . The double KO for MKK3 and MKK6 is also embryonic lethal and shows a similar phenotype to the p38a KO [13] . Moreover, there is evidence that p38a and p38b play overlapping in vivo functions during mouse development [14] . Genetically modified mice have provided evidence showing that p38a signaling plays an important role controlling inflammation, as well as the proliferation, differentiation and survival of different cell types [15, 16] . Here, we discuss the roles of p38a in mouse models of inflammatory diseases and cancer.
p38a MAPK in inflammatory diseases
There is in vivo and in vitro evidence linking p38a signaling to the production of inflammatory mediators and pro-inflammatory cytokines in several cell types via transcriptional and post-transcriptional mechanisms [7, 16] .
Mice deficient for the p38a substrate MK2 provided the first in vivo evidence for the implication of this pathway in inflammation. The MK2 KO mice are more resistant to lipopolysaccharide (LPS)-induced endotoxic shock as a result of the reduced production of tumor necrosis factor-a (TNF-a) [17] . Additional studies show that the MK2-related kinase MK3 contributes to regulating LPS-induced TNF-a production in vivo, although to a lesser extent than MK2 [18] . The use of mice deficient for p38a either in myeloid cells or in epithelial cells has further supported the implication of this pathway in cytokine production and inflammatory responses in vivo [19] [20] [21] . The connection of p38a with the production of inflammatory mediators has prompted the use of mouse models to investigate the in vivo functions of this pathway in the pathogenesis of inflammatory diseases ( Fig. 1 and Table 1 ). It should be noted that p38b appears to be required neither for the acute, nor chronic inflammatory responses [11, 22] , whereas myeloid cells deficient in p38c and p38d are impaired in the LPSinduced production of several cytokines, which correlates with reduced levels of the MAPK kinase kinase (MAP3K) TPL-2 and extracellular signal-regulated kinase (ERK)1/2 signaling [23] . Interestingly, p38a activation does not appear to be affected by p38c and p38d downregulation [23] , suggesting that they regulate the inflammatory response by distinct mechanisms.
Rheumatoid arthritis (RA)
RA is an autoimmune and chronic inflammatory disorder that affects the joints of hands and feet. Both p38 MAPK and the activators MKK3 and MKK6 are phosphorylated in their activation residues in synovial tissue from RA patients [24, 25] , suggesting the implication of p38 MAPK signaling in RA. In a collageninduced model of experimental arthritis (CIA), the p38 MAPK inhibitor SD-282 attenuates disease progression and reverses cartilage and bone destruction [26, 27] . There is evidence that only p38a but not p38b is involved in collagen-antibody or TNF-a-driven arthritis [22] . Deficiency of MK2 protects against CIA Table 1 . by reducing the serum levels of interleukin (IL)-6 and TNF-a [28] , suggesting that MK2 plays a critical role downstream of p38a signaling in arthritis. Disruption of the p38 MAPK activators MKK3 and MKK6 or the MAP3K apoptosis signal-regulating kinase 1 (ASK1) also protects against experimental arthritis [29] [30] [31] . These studies suggest that inhibition of p38 MAPK signaling may have therapeutic potential in arthritis patients. However, a recent study shows that p38a downregulation in myeloid cells exacerbates the severity of arthritis symptoms [32] . This p38a effect could be mediated through the substrates mitogenand stress-activated protein kinase (MSK)-1 and -2, which control transcriptional activation of the antiinflammatory cytokine IL-10 [33] . Collectively, p38a signaling appears to have both pro-and anti-inflammatory roles, which could explain the modest effect of p38 MAPK inhibitors in RA patients [34, 35] . Targeting of the activators MKK3 and MKK6 or the substrate MK2 has been proposed as alternative therapeutic strategy in RA aiming to avoid the antiinflammatory effects of p38a [32, 36] . In support of this idea, treatment of rats with the MK2 inhibitor PF-3644022 reduces both LPS-induced TNF-a production and chronic inflammation in the streptococcal cell wall-induced arthritis model [37] .
Multiple sclerosis (MS)
MS is an inflammatory disease of the central nervous system that affects young adults. MS can be modeled in mice by immunization with myelin antigen combined with adjuvant, termed experimental autoimmune (or allergic) encephalomyelitis (EAE). EAE development requires elevated cytokine expression levels, which are also detected in MS patients. Interestingly, p38a is upregulated in MS lesions and the levels of phosphorylated p38 MAPK are enhanced in EAE rat models [38] , suggesting the implication of p38 MAPK in EAE. In agreement with this idea, p38 MAPK inhibitors markedly suppress EAE in mouse models, correlating with decreased IL-17 levels [39, 40] . Furthermore, downregulation of p38a or its activator ASK1 ameliorates the severity of EAE [39, 41, 42] . By contrast to the above results, mice deficient in the p38a substrate MK2 show a delayed onset of EAE but prolonged disease activity, which is probably the result of a lack of TNF-a and an altered immune response in the central nervous system [43] . These results suggest a predominant role for p38a substrates other than MK2 in the regulation of EAE development. Recent studies show that p38a autophosphorylation is required for the production of IL-17 by T cells and impairment of this alternative activation pathway reduces EAE severity in mice [44] . Expression in T cells of a nonphosphorylatable p38a mutant, which is considered to work in a dominant-negative manner, or the deletion of the activators MKK3 and MKK6, greatly reduces phosphorylation of p38 MAPK, production of IL-17 and EAE symptoms in mice [40] . Conversely, forced activation of p38 MAPK in mouse T cells by expression of constitutively active MKK6 results in enhanced IL-17 production and an increased susceptibility to EAE [40] . However, specific deletion of p38a in T cells does not affect EAE development [42] . This might be explained by insufficient downregulation of p38a in T cells or by compensation via other p38 MAPK family members because p38b has a partial redundant role in T cell function [44] . Deletion of p38a in macrophages does not affect EAE development, whereas deletion of p38a in CD11c + dendritic cells (DCs) reduces EAE symptoms, as well as the expression of IL-6 and differentiation of T cells producing IL-17 (TH17) [42] . These results suggest that p38a-dependent expression of IL-6 in DCs is required for TH17 differentiation and EAE development [42] . Altogether, p38a activation in DCs and T cells appears to be important for the pathogenesis of EAE, suggesting that targeting this pathway might have therapeutic value in MS.
Atherosclerosis
Atherosclerosis is a chronic inflammatory cardiovascular disease and a leading cause of both mortality and morbidity worldwide. The atherogenic process has been widely studied using mice deficient either for apolipoprotein E (ApoE), which develop spontaneous atherosclerosis, or for low-density lipoprotein receptor (Ldlr), which need a cholesterol diet to develop hypercholesterolemia and atherosclerosis.
Mice deficient for the p38a substrate MK2, which are impaired in pro-inflammatory cytokine production [17] , are resistant to atherosclerosis by reducing vascular lipid deposition and macrophages in hypercholesterolemic Ldlr À/À mice. MK2 also regulates aortic expression of the vascular cell adhesion molecule (VCAM)-1 and the chemokine monocyte chemoattractant protein (MCP)-1, which are key for the recruitment of monocytes/macrophages to the vascular wall [45] . p38 MAPK has also been suggested to regulate the pro-atherogenic molecules VCAM-1 and MCP-1 in ApoE À/À mice [46] . These studies support the implication of p38 MAPK signaling in the development of atherosclerosis, although the cell type responsible remains unclear. Phosphorylated MK2 is detected in the endothelium and macrophage-rich pla-que areas within aortas of hypercholesterolemic Ldlr À/À mice, suggesting that atherosclerosis development might involve p38a activation in these cells. Surprisingly, p38a downregulation in macrophages does not affect the formation of atherosclerotic plaques or macrophage recruitment in ApoE À/À mice but, instead, leads to macrophage apoptosis and other markers of advanced plaque progression, which were not checked in the MK2 KO mice, by suppressing AKT activation [47] . It was subsequently shown that the inhibition of p38a or both MK2 and MK3 impairs the LPS-induced activation of AKT in bone-marrow derived macrophages, although KO of either MK2 or MK3 alone has little effect on AKT phosphorylation [48] . It is therefore possible that p38a plays a pro-survival role in the macrophages of advanced atherosclerotic plaques, whereas a deficiency of MK2 alone does not affect the AKT survival pathway. Thus, the phenotype of MK2 KO mice might be a result of the role of MK2 in other cells, such as endothelial cells. By contrast to this possibility, a recent study reports that endothelial or macrophage specific-downregulation of p38a affects neither the development, nor the characteristics of atherosclerotic plaques in ApoE À/ À mice [49] . The controversial findings could be explained by the different genetic backgrounds of the mice used in the studies, which can influence the extent of atherosclerosis in ApoE À/À mice [50] . More studies are warranted to define the role of p38a signaling in atherosclerosis, especially regarding the analysis of other cell types that could be involved, such as smooth muscle cells.
Chronic obstructive pulmonary disease (COPD)
The p38 MAPK pathway has been linked to lung inflammatory diseases such as COPD and asthma. Phosphorylated p38 MAPK has been detected in both alveolar macrophages and the alveolar walls of COPD patients [51] . Increased activation of p38 MAPK has been also reported in alveolar macrophages of patients with severe asthma [52] . Activation of p38 MAPK in alveolar macrophages may induce the secretion of proinflammatory cytokines and chemokines required for the pathogenesis of COPD. Inhibition of p38 MAPK using SD-282 reduces inflammation in a model of tobacco smoke-induced airway inflammation with decreased expression of cyclooxygenase-2 (COX-2) and IL-6 mRNAs [53] . Studies using pharmacological inhibitors have also implicated p38 MAPK in mouse models of COPD, asthma and acute lung inflammation [54] [55] [56] [57] , suggesting that p38 MAPK inhibition could have therapeutic effects in lung inflammatory diseases. 
p38a MAPK in cancer

Breast cancer
Mouse models have provided in vivo evidence for the implication of p38 MAPK signaling in breast cancer. Studies using mice deficient in Wip1, a phosphatase that can target p38a, show significantly reduced breast tumorigenesis upon expression of Erbb2 or H-Ras, which correlates with higher p38 MAPK activation [68] . The p38a and p38b inhibitor SB203580 restores the Erbb2 driven tumorigenesis in Wip1 KO mice, suggesting that p38 MAPK hyperactivation contributes to the reduced breast tumorigenesis observed in the absence of Wip1. Conversely, mice overexpressing Wip1 in the breast epithelium are more susceptible to breast tumor development induced by ErbB2, a phenotype that was attenuated upon co-expression of constitutively active MKK6 to activate the p38 MAPK pathway [69] . Mice deficient in Gadd45a, an activator of the c-Jun N-terminal kinase (JNK) and p38 MAPK pathways, also show accelerated breast tumorigenesis induced by Ras, which correlates with reduced activa- tion of p38 MAPK and reduced levels of Ras-induced senescence [70] . By contrast to the above tumor suppressive role in breast tumor initiation, recent reports suggest that p38 MAPK signaling may also play pro-tumorigenic roles. For example, the p38a and p38b inhibitor PH797804 impairs the growth of breast tumors induced by polyoma middle T (PyMT), which correlates with increased apoptosis and decreased proliferation of tumor cells [71] . Interestingly, p38 MAPK inhibition potentiates the chemotherapeutic drug cisplatin, reducing the size and malignancy of PyMT-induced breast tumors. At the molecular level, inhibition of p38 MAPK results in reactive oxygen species (ROS)-dependent upregulation of the JNK pathway, which in turn mediates cisplatininduced apoptosis [71] . The inhibitor LY2228820 also reduces tumor growth in a xenograft model based on the MDA-MB-468 breast cancer cell line [72] . These results indicate that p38 MAPK signaling contributes to breast tumor progression in mouse models.
The pro-tumorigenic role of p38 MAPK is also supported by experiments showing that inhibition of this pathway impairs the proliferation of p53 mutant and estrogen receptor-negative breast cancer cell lines in vitro [73] . Of note, both MDA-MB-468 cells and PyMT breast tumors are estrogen receptor-negative. Moreover, high levels of active p38 MAPK have been correlated with invasive and poor prognostic breast cancers, lymph node metastasis and tamoxifen resistance in patients [74] [75] [76] [77] . Activation of p38 MAPK signaling downstream of the ubiquitin-conjugating enzyme Ubc13 has been shown to contribute to metastasis and lung colonization by human and mouse breast cancer cells [78] . Taken together, it appears that p38 MAPK inhibitors, either alone or in combination with chemotherapeutic drugs, could help to reduce breast tumor growth and metastasis.
Lung cancer
Studies using p38a conditional KO mice have provided in vivo evidence for the involvement of p38 MAPK in lung homeostasis [66, 67] . Embryo-specific deletion of p38a results in perinatal death as a result of distorted alveolar structures and massive infiltration of hematopoietic cells in the lungs [66] . Postnatal deletion of p38a results in increased proliferation and defective differentiation of the lung stem and progenitor cells, which can be accounted for by the upregulation of epidermal growth factor receptor (EGFR) and lower expression of the transcription factor C/EBPa [67] . Moreover, p38a signaling in lung stem cells induces the expression of CXCL-12 that activates the stromal fibroblasts, whereas the endogenous p38a in lung fibroblasts is required for the induction of cytokines, which in turn trigger the recruitment of endothelial cells [79] . These results support a key role for p38a in maintaining a functional lung microenvironment, suggesting that disruption of this signaling pathway may lead to lung diseases. In line with this idea, the altered lung homeostasis observed upon p38a downregulation facilitates lung tumorigenesis induced by oncogenic K-ras G12V [67] . The p38a-deficient lung tumors exhibit poor differentiation and higher mitotic indices, which correlate with reduced levels of the differentiation markers C/EBPa and hepatocyte nuclear factor 3b (HNF3b), and with increased activation of AKT and EGFR signaling [67] . The phenotype observed in p38a-deficient lungs mimics the early stages of K-ras G12V induced transformation, suggesting that the enhanced tumorigenesis might be related to changes in the lung cellular microenvironment rather than to the negative regulation of oncogenic signaling by p38a in tumor cells.
Deletion of the p38a substrate MK2 has no effect on the initiation of lung tumorigenesis in a similar mouse model, irrespective of the p53 status. However, MK2 restrains the progression of lung tumors in the absence of p53 but has no effect when p53 is expressed. MK2 disruption not only makes p53-deficient lung tumors grow faster, but also sensitizes to DNA damage-inducing drugs such as cisplatin [80] .
Increased p38 MAPK phosphorylation has been reported in human lung tumors compared to normal tissue [81] , suggesting that p38 MAPK might contribute to lung tumor progression. The regulation of lung inflammation by p38 MAPK signaling may also impinge on tumorigenesis, although it is unclear whether lung inflammatory diseases such as COPD and asthma are linked to increased risk of lung cancer [82] . Further work is required to elucidate whether p38 MAPK inhibition might help lung cancer patients.
Liver cancer p38a negatively regulates hepatocyte proliferation in adult mice during liver regeneration after partial hepatectomy or N-nitrosodiethylamine (DEN)-induced liver injury. Inactivation of c-Jun in p38a deficient livers results in normal hepatocyte proliferation, suggesting that activation of the JNK-c-Jun pathway is responsible for the enhanced proliferation of p38a deficient hepatocytes [66] .
Uncontrolled hepatocyte proliferation is considered to be important for liver cancer development. Hepatocellular carcinoma (HCC) is one of the most common forms of primary liver cancer in humans, with 70-90% of HCC cases occurring in patients with chronic liver diseases and cirrhosis, mainly as a result of hepatitis B virus infection and alcoholic liver disease [83] . To study HCC in mice, DEN is used as an initiator and phenobarbital (Pb) as a promoting agent. Hepatocyte-specific deletion of p38a facilitates DEN/Pbinduced HCC, in which upregulation of the JNK-cJun pathway plays an important role by enhancing proliferation of p38a-deficient tumor cells [66] . p38a has been proposed to suppress ROS accumulation by modulating Hsp27 expression and cell death in DEN-treated hepatocytes. Dying hepatocytes release IL-1a, which stimulates DEN-induced hepatocyte proliferation, facilitating HCC development [84] . Similar results have been observed in a model of HCC related to liver cirrhosis, in which p38a deficiency in hepatocytes leads to ROS accumulation and enhanced thioacetamide-induced liver damage and fibrosis [85] . Another study using a model of LPS/TNF-induced liver damage has shown that hyperactivation of the JNK pathway in p38a-deficient hepatocytes is not sufficient to mediate TNF-induced liver toxicity [86] . However, the combined downregulation of p38a and IKK2 in hepatocytes results in liver failure upon LPS injection, suggesting that p38a collaborates with the nuclear factor kappa B (NF-kB) pathway to protect the liver from cytokine-induced damage by antagonizing JNK activation [86] . These studies indicate that p38a can suppress HCC by regulating different molecular mechanisms depending on the stimuli.
In agreement with the observation that p38a suppresses HCC development in mouse models, reduced p38 MAPK and MKK6 activities have been reported in human HCC compared to nontumoral tissue [87] . Moreover, phosphorylation of the p38a pathway target Hsp27 has been inversely correlated with tumor size, invasion and tumor stages of human HCCs [88] . By contrast, another study positively correlated p38 MAPK phosphorylation with HCC tumor size and poor survival, although nontumoral areas were not analyzed [89] . A larger cohort of human HCC samples should be analyzed to obtain conclusive data on the role of p38 MAPK signaling in human HCC progression.
Colon cancer
The colon is part of the lower gastrointestinal tract. The intestinal epithelia serve as a barrier and play an important role in protecting the intestinal tract against luminal invading pathogens and ingested toxin, which can promote inflammatory responses. Colon inflammatory diseases such as inflammatory bowel disease (IBD) are associated with higher risk of colorectal cancer (CRC) development [90] .
In vivo roles of p38a in colon homeostasis and tumor development have been studied using mice with p38a downregulation in intestinal epithelial cells (IECs) [21, 91, 92] . These mice appear healthy but show changes in intestinal homeostasis, including increased IEC proliferation, which is associated with increased ERK1/2 and EGFR signaling [91] , as well as reduced numbers of mucus producing goblet cells [21, 91, 92] . Moreover, p38a regulates the assembly of intestinal epithelial tight junctions, probably by controlling the expression of ZO-1 and other tight junction molecules [92] .
Mice with IEC-specific p38a downregulation are more susceptible to dextran sodium sulfate (DSS)-induced colitis [21, 91, 92] . DSS is toxic and induces epithelial cell apoptosis, which initiates intestinal inflammation and colitis in mice, and there is evidence that p38a plays a critical role protecting from epithelial apoptosis, thus preventing DSS-induced colitis [21, 91, 92] . Increased apoptosis correlates with increased JNK activation and accumulation of the pro-apoptotic protein Bak in p38a-deficient IEC [91, 92] . Importantly, the enhanced colitis observed in these mice can be rescued by the administration of probiotics, which restore the altered epithelial permeability, supporting that regulation of the epithelial barrier function by p38a is critical for protection against DSS-induced colitis [92] . By contrast to the role of p38a in IEC, downregulation of p38a in myeloid cells reduces inflammatory responses and colon epithelial damage during DSS-induced colitis [21] . This correlates with reduced activity of NF-kB and reduced expression of the inflammatory mediators COX-2 and IL-6 in the DSS-treated mice [21] . Thus, p38a signaling in different cell types appears to affect colitis progression differently. Of note, p38a in IEC not only regulates colon epithelial homeostasis, but also controls the expression of chemokines, which are essential for the recruitment of immune cells such as CD4 + T cells and subsequent clearance of Citrobacter rodentium infection [93] . These studies indicate that p38a signaling in IEC is critical for the protection against DSS-induced colitis and mucosal infections.
Chronic infection and inflammation can lead to colon tumor development. The initial stages of inflammationassociated colon tumorigenesis are suppressed by p38a [92, 94] . This is probably a result of the ability of p38a to regulate colon homeostasis and the epithelial barrier function [92] . Similarly, mice deficient in the p38a activator ASK1 show enhanced DSS-induced epithelial injury and inflammation and are more susceptible to inflammation-associated colon tumorigenesis [95] .
By contrast to the negative role of p38a in colon tumor initiation, p38 MAPK signaling can also perform pro-tumorigenic functions in established colon tumors. Mice xenografted with colon cancer cell lines or expressing APC min that are treated with the inhibitor SB202190 show reduced tumor growth, which correlates with a switch from HIF1a-to FoxO-dependent transcription that affects glycolytic metabolism [96] . Importantly, downregulation of p38a in colon tumor cells or pharmacological inhibition using PH797804 reduces tumor burden in mice, which correlates with activation of the JNK pathway, reduced expression of the anti-apoptotic protein Mcl-1 and downregulation of IL-6/STAT3 signaling [92] . Colon tumor growth is also reduced in azoxymethane-treated APC min mice by the combined inhibition of p38 MAPK using SB202190 and ERK1/2 signaling using PD0325901 [97] . These studies suggest a dual role for epithelial p38a signaling, suppressing inflammation-associated colon tumor initiation but supporting colon tumor progression.
There is also evidence implicating p38a in colon cancer metastasis. In particular, reduced levels of p38 MAPK activity in colon cancer cells facilitate lung colonization from established liver metastasis by enhancing production of the cytokine PTHLH, which in turn induces endothelial cell death, enabling tumor cell extravasation to the lung [98] . Taken together, p38a signaling appears to control colon tumor cell survival, proliferation and metastasis through distinct mechanisms.
As noted above, IBD patients have higher risk of developing CRC [90] . The activating phosphorylation of p38 MAPK in IBD patients has been evaluated in several studies that yield contradictory results [99] [100] [101] . Accordingly, the use of p38 MAPK inhibitors in clinical trials has not shown promising results. In patients with Crohn's disease, the p38 MAPK and JNK inhibitor CNI-1493 showed some clinical improvement [102] , whereas the p38 MAPK inhibitor BIRB796 showed no improvement [103] . Mouse studies indicate that, during DSS-induced colitis, p38a contributes to different functions in various cell types, which could explain the controversial effects reported using p38 MAPK inhibitors for therapy. In human CRC, enhanced levels of phosphorylated p38 MAPK have been reported both in tumor cells and in stromal cells [97, [104] [105] [106] , suggesting a pro-tumorigenic role of p38 MAPK. Moreover, high levels of phosphorylated p38 MAPK have been correlated with resistance to the chemotherapeutic drug irinotecan, as well as with poor overall survival in colon cancer patients [104, 106] . Collectively, p38 MAPK inhibition in colon cancer patients appears as an attractive therapeutic possibility, although caution is warranted because p38 MAPK inhibition can result in adverse effects.
Skin cancer
Mice deficient for the p38 MAPK substrate PRAK (also known as MK5) show enhanced 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin carcinogene-sis, which correlates with compromised senescence induction. In primary cells, inactivation of PRAK prevents senescence and promotes oncogenic transformation. The direct phosphorylation of p53 by PRAK has been proposed to mediate these effects [107] . Interestingly, PRAK can also promote the growth of skin tumors induced by DMBA and 12-O-tetradecanoylphorbol-13-acetate (TPA) via regulation of tumor angiogenesis. However, this effect is mediated by PRAK signaling in endothelial cells rather than in keratinocytes. Thus, in endothelial cells, tumor-secreted pro-angiogenic factors activate vascular endothelial growth factor receptor 2, which in turn activates PRAK inducing migration of the endothelial cells and their incorporation into tumor vasculature. This PRAK function may be mediated by the phosphorylation of the focal adhesion kinase FAK and cytoskeletal reorganization [108] . Of note, PRAK has been reported to also be a substrate of the MAPKs ERK3 and ERK4 [109] , and further studies are required to validate the contribution of p38a to PRAK activation in skin carcinogenesis. The p38a activator ASK1 has been also proposed to have a dual role in DMBA/TPA-induced skin carcinogenesis, facilitating tumor promotion via regulation of the inflammatory response at the same time as playing a tumor suppressive role by cooperating with ASK2 in keratinocytes [110] .
Mice deficient in Gadd45a show increased UVinduced skin carcinogenesis, which correlates with reduced levels of phosphorylated JNK and p38 MAPK, as well as reduced p53 levels and apoptosis [111] . Additionally, inhibition of p38 MAPK signaling has been associated with impaired capacity to repair UV-induced DNA damage, a primary risk factor for human skin cancers. The levels of p38a are decreased in human cutaneous squamous cell carcinomas (SCC) and UV irradiation of p53-deficient A431 keratinocytes (derived from SCC) decreases p38a expression. Consistently, treatment of p53 À/À SKH-1 mice with the p38 MAPK inhibitor SB203580 accelerates UVinduced SCC carcinogenesis and increases the expression of the NAPDH oxidase Nox2. These findings support a tumor-suppressive role for p38a in SCC pathogenesis, which is associated with the regulation of Nox2 [112] . By contrast to the above observations, another study has implicated the p38a substrate MK2 in skin tumor development. MK2 deficient mice show reduced skin carcinogenesis after treatment with DMBA/TPA, which has been explained by the implication of MK2 in the production of pro-inflammatory cytokines and in the regulation of p53-dependent apoptosis [113] . Similarly, combined deficiency of the p38a substrates MSK1 and MSK2 results in reduced skin carcinogenesis [114] . However, the expression of IL-1b and TNF-a is upregulated in MSK1/2 double KO mice, probably as a result of weakened negative feedback loops that limit the inflammatory response [33] . Therefore, a defective inflammatory response is unlikely to account for the reduced skin tumorigenesis observed in MSK1/ 2 double KO mice, which might be a result of impaired p38 MAPK-triggered keratinocyte proliferation. Indeed, p38 MAPK signaling in keratinocytes has been reported to contribute to skin carcinogenesis by inducing activation of the transcription factor activator protein-1 (AP-1) and expression of COX-2, which stimulate the proliferation of UVB-irradiated epidermal keratinocytes [115] . Mice expressing a p38a mutant protein, which may work in a dominant-negative manner, also show reduced skin tumorigenesis in response to solar UV irradiation, suggesting that p38 MAPK activation by solar UV contributes to skin carcinogenesis [116] .
Conclusions
There is good evidence implicating p38a signaling in inflammatory diseases, as well as during tumor initiation and progression (Table 1) . The in vivo experiments using genetically modified mice and the use of pharmacological inhibitors suggest that targeting p38a signaling could be useful for the treatment of some inflammatory diseases. Several p38 MAPK inhibitors have been tested in clinical trials but have failed mainly as a result of side effects, such as skin rashes and liver toxicity. However, it is not clear whether these side effects are a result of the systemic inhibition of p38 MAPK signaling or the off-target effects of the inhibitors. Nevertheless, promising results have been obtained in some cases [117] , although systemic inhibition of the p38 MAPK pathway may not be beneficial in all the cases. Based on the studies using mouse models, p38a appears to have distinct roles in different cell types even within the same tissue. For example, inhibition of p38a in myeloid cells ameliorates the effects of colitis, whereas inhibition of p38a in IEC can have deleterious effects in the same model. This dual effect could explain the failure of p38 MAPK inhibitors in IBD patients.
Given the contribution of inflammation to tumorigenesis, inhibition of p38a signaling would be expected to benefit inflammation-associated cancers. However, mouse studies indicate that the role of p38a signaling in cancer initiation and progression is cell type-and tumor type-dependent. Because p38a may suppress some type of tumors at the same time as working as a tumor promoter in other cancers, the inhibitors should be used with caution. Thus, new strategies to target p38a signaling in cell type or tissue specific manners should be devised. Moreover, considering the crosstalk among signaling pathways, it might be beneficial to use combination therapies for simultaneously targeting p38a and other signaling molecules. It should be noted that genetic analysis in mice have also implicated p38c and p38d in the in vivo regulation of colitis-associated colon tumorigenesis [118] and skin cancer [119] . It remains to be established whether different p38 MAPK family members might interplay during tumor development.
Recent studies have improved our understanding of the in vivo roles of p38a signaling in inflammation and cancer. Tumor-suppressing and tumor-promoting functions of the p38a pathway can be temporally and spatially separated during tumor development, depending on the tissue type and the tumor stage. More mechanistic studies are required to define the functions of p38a, as well as its key regulators and targets in mouse models of cancer. Future studies should also focus on the development of new models to regulate the p38 MAPK pathway in a time-and cell type-dependent manner. These new models should provide valuable information on the role of p38a signaling at various stages of the disease and in different cell types, which in turn should be useful for developing improved therapeutic strategies.
